(Q36352079)

13 August 2017

1 reference

title

Current and future status of prostate cancer chemoprevention (English)

1 reference

13 August 2017

1 reference

Naohiro Fujimoto

1

1 reference

13 August 2017

Masayoshi Nomura

series ordinal

2

1 reference

13 August 2017

Tetsuro Matsumoto

series ordinal

3

1 reference

13 August 2017

publication date

1 January 2006

1 reference

Expert Review of Anticancer Therapy

13 August 2017

published in

1 reference

13 August 2017

volume

6

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

59-71

1 reference

Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Molecular biomarker in prostate cancer: the role of CpG island hypermethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

5α-Reductase Type 1 Immunostaining is Enhanced in Some Prostate Cancers Compared With Benign Prostatic Hyperplasia Epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Prevention of prostate cancer with finasteride: US/European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17 beta-estradiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

The Role of Soy Products in Reducing Risk of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Diet and its preventive role in prostatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Role of peptide growth factors in the prostate: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Activation of oncogenes and/or inactivation of anti-oncogenes by reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Lack of modification by naturally occurring antioxidants of 3,2′-dimethyl-4-aminobiphenyl-initiated rat prostate carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Inhibitory effects of selenium on the growth of DU-145 human prostate carcinoma cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Selenium and immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Comparison of the effects of an organic and an inorganic form of selenium on a mammary carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

A prospective study of plasma selenium levels and prostate cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Antioxidant dietary supplements: Rationale and current status as chemopreventive agents for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Physical activity and prostate cancer in the Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study (Finland).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

gamma-Tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Biological activities of natural and synthetic carotenoids: induction of gap junctional communication and singlet oxygen quenching.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Lycopene and 1,25-dihydroxyvitamin D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Lycopene oxidation product enhances gap junctional communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Cohort study of diet, lifestyle, and prostate cancer in Adventist men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Intake of carotenoids and retinol in relation to risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Do dietary lycopene and other carotenoids protect against prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Medicinal benefits of green tea: part II. review of anticancer properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

The role of cyclooxygenase-2 in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

The coxibs, selective inhibitors of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

The steroid hormone dehydroepiandrosterone inhibits CYP1A1 expression in vitro by a post-transcriptional mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Biological determinants of cancer progression in men with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Agents in development for prostate cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Epidemiology of inflammation and prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

Prostate carcinogenesis and inflammation: emerging insights.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.59

21 January 2018

Identifiers

DOI

10.1586/14737140.6.1.59

1 reference

13 August 2017

1 reference